Patent intelligence · US
US 11365246
Anti CCL24 (EOTAXIN2) antibodies for use in the treatment of hepatic diseases
Anti CCL24 (EOTAXIN2) antibodies for use in the treatment of hepatic diseases
Patent details — US 11365246
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jun 21, 2022
- Expiration
- Jun 16, 2042
- Applicant
- CHEMOMAB LTD.
- Claims
- 4
- CPC classes
- A61K, A61K2039/505, A61K39/3955, A61K45/06
Quick answer
US 11365246 (Anti CCL24 (EOTAXIN2) antibodies for use in the treatment of hepatic diseases) is held by CHEMOMAB LTD.. Status: granted. Granted Jun 21, 2022. Expires Jun 16, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- CHEMOMAB LTD.
- Grant date
- Expiration
- Claims
- 4
- CPC classes
- A61K, A61K2039/505, A61K39/3955, A61K45/06, A61P, A61P1/16
More from CHEMOMAB LTD.
Related pharmaceutical patents in our USPTO index.
Frequently asked questions
What is US patent 11365246?
US 11365246 (Anti CCL24 (EOTAXIN2) antibodies for use in the treatment of hepatic diseases) is held by CHEMOMAB LTD.. Status: granted. Granted Jun 21, 2022. Expires Jun 16, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11365246?
CHEMOMAB LTD. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 4 pharmaceutical patents for this assignee.
When does US 11365246 expire?
Our index shows an expiration date of Jun 16, 2042 (16 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.